New hope for young adults with CML: asciminib under Real-World scrutiny
NCT ID NCT07681258
First seen Jul 02, 2026 · Last updated Aug 11, 2026 · Updated 4 times
Summary
This study looks at how well the drug asciminib works and how safe it is for young adults with chronic myeloid leukemia (CML) in the Gulf region. Researchers will collect information from medical records of about 80 people aged 18 and older who have taken asciminib. The main goal is to see how many achieve a major molecular response, a key sign that the leukemia is well controlled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- asciminib
- What this could lead to
- If asciminib proves safe and effective in this younger population, it could offer a new treatment option for chronic myeloid leukemia.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less definitive. Side effects are possible, and the small sample size may limit generalizability.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a smart tool keep watch on leukemia after treatment stops?
- Can donor immune cells tame stem cell transplant risks?
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Could bone marrow from deceased donors cure blood cancers?
- Engineered t cells with a kill switch aim to make stem cell transplants safer